RU2009111273A - 5-SUBSTITUTED ISOINDOLINE COMPOUNDS - Google Patents
5-SUBSTITUTED ISOINDOLINE COMPOUNDS Download PDFInfo
- Publication number
- RU2009111273A RU2009111273A RU2009111273/04A RU2009111273A RU2009111273A RU 2009111273 A RU2009111273 A RU 2009111273A RU 2009111273/04 A RU2009111273/04 A RU 2009111273/04A RU 2009111273 A RU2009111273 A RU 2009111273A RU 2009111273 A RU2009111273 A RU 2009111273A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- optionally substituted
- compound
- halogens
- alkoxy
- Prior art date
Links
Abstract
1. Соединение формулы (I) !! или его фармацевтически приемлемая соль, сольват или стереоизомер, в котором ! n равно 0 или 1; ! Х представляет СН2, С=О или C=S; ! R1 представляет: ! а) -(CH2)mR3 или -СО(CH2)mR3, где ! m равно 0, 1, 2 или 3; и ! R3 представляет 5-10-членный арил или гетероарил, необязательно замещенный одним или несколькими галогенами; ! b) -C=YR4, где ! Y представляет О или S; и ! R4 представляет: ! (C1-C10)алкил; (C1-C10)алкокси; ! (C0-C10)алкил-(5-10-членный гетероарил или гетероцикл), указанный гетероарил или гетероцикл необязательно замещен одним или несколькими заместителями из (C1-C6)алкила, галогена, оксо, (C1-C6)алкокси, или -Z-(C1-C6)алкила, где Z представляет S или SO2, и где указанный (C1-C6)алкил может быть необязательно замещен одним или несколькими галогенами; ! (C0-C10)алкил-(5-10-членный арил), указанный арил необязательно замещен одним или несколькими заместителями из галогена; (C1-C6)алкокси, который сам необязательно замещен одним или несколькими галогенами; (C1-C6)алкила, который сам необязательно замещен одним или несколькими галогенами; или -Z-(C1-C6)алкила, где Z представляет S или SO2, и где указанный (C1-C6)алкил может быть необязательно замещен одним или несколькими галогенами; или ! (C1-C6)алкил-СО-О-R12, где R12 представляет Н или (C1-C6)алкил; или ! с) -C=ZNHR6, где ! Z представляет О или S; и ! R6 представляет ! (C1-C10)алкил; (C1-C10)алкокси; ! 5-10-членный арил или гетероарил, необязательно замещеный одним или несколькими заместителями из галогена; циано; (C1-C6)алкилендиокси; (C1-C6)алкокси, который сам необязательно замещен одним или несколькими галогенами; (C1-C6)алкила, который сам необязательно замещен одним или несколькими галогенами; (C1-C6)алкилтио, который сам необязательно замещен одни 1. The compound of formula (I) !! or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, in which! n is 0 or 1; ! X represents CH2, C = O or C = S; ! R1 represents:! a) - (CH2) mR3 or -CO (CH2) mR3, where! m is 0, 1, 2 or 3; and! R3 is a 5-10 membered aryl or heteroaryl optionally substituted with one or more halogens; ! b) -C = YR4, where! Y represents O or S; and! R4 represents:! (C1-C10) alkyl; (C1-C10) alkoxy; ! (C0-C10) alkyl- (5-10 membered heteroaryl or heterocycle), said heteroaryl or heterocycle is optionally substituted with one or more substituents of (C1-C6) alkyl, halogen, oxo, (C1-C6) alkoxy, or -Z - (C1-C6) alkyl, where Z is S or SO2, and wherein said (C1-C6) alkyl may optionally be substituted with one or more halogens; ! (C0-C10) alkyl- (5-10 membered aryl), said aryl is optionally substituted with one or more halogen substituents; (C1-C6) alkoxy, which itself is optionally substituted with one or more halogens; (C1-C6) alkyl, which itself is optionally substituted with one or more halogens; or -Z- (C1-C6) alkyl, where Z is S or SO2, and wherein said (C1-C6) alkyl may optionally be substituted with one or more halogens; or ! (C1-C6) alkyl-CO-O-R12, wherein R12 is H or (C1-C6) alkyl; or ! c) -C = ZNHR6, where! Z represents O or S; and! R6 presents! (C1-C10) alkyl; (C1-C10) alkoxy; ! 5-10 membered aryl or heteroaryl optionally substituted with one or more halogen substituents; cyano; (C1-C6) alkylenedioxy; (C1-C6) alkoxy, which itself is optionally substituted with one or more halogens; (C1-C6) alkyl, which itself is optionally substituted with one or more halogens; (C1-C6) alkylthio, which itself is optionally substituted alone
Claims (30)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84136506P | 2006-08-30 | 2006-08-30 | |
US60/841,365 | 2006-08-30 | ||
US92551307P | 2007-04-20 | 2007-04-20 | |
US60/925,513 | 2007-04-20 | ||
US60/937,782 | 2007-06-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2009111273A true RU2009111273A (en) | 2010-10-10 |
RU2448101C2 RU2448101C2 (en) | 2012-04-20 |
Family
ID=44024502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2009111273/04A RU2448101C2 (en) | 2006-08-30 | 2007-08-29 | 5-substituted isoindoline compounds |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2448101C2 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6778114B2 (en) * | 2014-04-14 | 2020-10-28 | アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. | Imid-based proteolysis modulators and related uses |
US20170327469A1 (en) | 2015-01-20 | 2017-11-16 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
MX2017009454A (en) | 2015-01-20 | 2017-10-20 | Arvinas Inc | Compounds and methods for the targeted degradation of the androgen receptor. |
US20180147202A1 (en) | 2015-06-05 | 2018-05-31 | Arvinas, Inc. | TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE |
WO2017030814A1 (en) | 2015-08-19 | 2017-02-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
HRP20230414T1 (en) | 2016-10-11 | 2023-07-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
KR20230127371A (en) | 2016-11-01 | 2023-08-31 | 아비나스 오퍼레이션스, 인코포레이티드 | Tau-protein targeting protacs and associated methods of use |
AU2017366693B2 (en) | 2016-12-01 | 2021-04-01 | Arvinas Operations, Inc. | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
IL294423B2 (en) | 2016-12-23 | 2024-01-01 | Univ Yale | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
WO2018119441A1 (en) | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Egfr proteolysis targeting chimeric molecules and associated methods of use |
US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
EP3573977A4 (en) | 2017-01-26 | 2020-12-23 | Arvinas Operations, Inc. | Modulators of estrogen receptor proteolysis and associated methods of use |
EP3710443A1 (en) | 2017-11-17 | 2020-09-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
BR112020020307A2 (en) | 2018-04-04 | 2021-01-12 | Arvinas Operations, Inc. | PROTEOLYSIS MODULATORS AND ASSOCIATED METHODS OF USE |
EP3841100A1 (en) | 2018-08-20 | 2021-06-30 | Arvinas Operations, Inc. | Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases |
US11912699B2 (en) | 2019-07-17 | 2024-02-27 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated |
AU2020405129A1 (en) | 2019-12-19 | 2022-06-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU228769B1 (en) * | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
-
2007
- 2007-08-29 RU RU2009111273/04A patent/RU2448101C2/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
RU2448101C2 (en) | 2012-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2009111273A (en) | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | |
RU2009114159A (en) | N-METHYLAMINOMETHYLISIDOID COMPOUNDS, COMPOSITIONS INCLUDING THEM, AND WAYS OF THEIR APPLICATION | |
JP2010503688A5 (en) | ||
RU2009138500A (en) | 4, -O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND CONTAINING THEIR COMPOSITIONS AND WAYS OF THEIR APPLICATION | |
RU2345077C2 (en) | PYRIDINE [2,3-d] PYRIMIDINE DERIVATIVES AS SELECTIVE KDR AND FGFR INHIBITORS | |
HRP20120447T1 (en) | 5-substituted quinazolinone derivatives as antitumor agents | |
RU2401658C2 (en) | Heterocyclic aspartylprotease inhibitors | |
RU2460730C2 (en) | Novel n-(8-heteroaryltetrahydro-naphthalen-2-yl)- or n-(5-heteroarylchroman-3-yl)-carboxamide derivatives for pain treatment | |
RU2010116273A (en) | 6-, 7-, or 8-SUBSTITUTED CHINAZOLINONE DERIVATIVES AND COMPOSITIONS, INCLUDING THEIR AND WAYS OF USING THEM | |
RU2003132687A (en) | TREATMENT OF TYPE 2 DIABETES BY DIPEPTIDYLPEPTIDASE IV INHIBITORS | |
RU2008129723A (en) | CCR9 ACTIVITY INHIBITORS | |
HRP20150119T1 (en) | N-substituted glycine derivatives: hydroxylase inhibitors | |
MA27390A1 (en) | DIOXANE-2-ALKYLCARBAMATES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | |
RU2017134013A (en) | Derivative Acid Derivatives As Agronists FXR / TGR5 AND METHODS OF THEIR APPLICATION | |
RU2008112221A (en) | COMPOUNDS OF A NUMBER OF ISOINDOLIMIDES, THEIR COMPOSITIONS AND METHODS OF APPLICATION | |
RU2005107314A (en) | Pyrimidine derivatives characterized by anti-proliferative activity | |
RU2002123350A (en) | Dipeptidnitrile Cathepsin K Inhibitors | |
JP2009514870A5 (en) | ||
RU2001135826A (en) | NEW USE OF COMPOUNDS AS ANTIBACTERIAL MEDICINES | |
RU2015123499A (en) | COMPOUNDS OF SUBSTITUTED TRIAZOLBORONIC ACID | |
JP2008545718A5 (en) | ||
EA200901573A1 (en) | Heteroaryl Thiazole Substituents | |
RU2007135023A (en) | Quinazoline derivatives with inhibitory activity against tyrosine kinase | |
RU2007128080A (en) | Pyrrolidinium derivatives as muscarinic receptors of the Ministry of Health | |
RU99101081A (en) | MODE OF INTRODUCTION OF H +, K + -ATPASE INHIBITORS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20120830 |